| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.057 | 0.2 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.068 | 0.2 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.075 | 0.2 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.095 | 0.2 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |